Highlights

  • LTR Pharma confirmed the first patient-specific ROXUS prescriptions have been fulfilled in the United States.
  • ROXUS is being supplied as a compounded intranasal medication through a telehealth and pharmacy pathway.
  • The company did not disclose prescription volumes, pricing or Revenue from the initial fulfilment activity.
  • LTR Pharma reported A$19.6 million in cash and no Debt in its October 2026 investor materials.
  • The company continues to progress a separate US regulatory pathway for SPONTAN.

LTR Pharma Limited (ASX:LTP) is a Brisbane-based biopharmaceutical company focused on commercialising fast-acting, non-invasive therapies using its intranasal drug-delivery platform. Its 6 October 2026 update confirmed that the first patient-specific ROXUS prescriptions have been fulfilled in the United States, marking the start of prescription activity through the company's US access pathway.

First US Prescription Fulfilment

LTR Pharma said ROXUS prescriptions are being received through a men's health telehealth channel, with a licensed US pharmacy handling compounding and distribution. The company did not state how many prescriptions had been fulfilled and did not provide pricing or revenue information for the initial activity.

ROXUS is an intranasal spray intended to support erectile dysfunction treatment. In the United States, it is supplied as a compounded medication under Section 503A of the federal Food, Drug, and Cosmetic Act. LTR Pharma stated that compounded ROXUS is not reviewed or approved by the US Food and Drug Administration for safety or efficacy.

Commercial Access and Prescription Commitments

In its October 2026 investor materials, LTR Pharma reported a minimum commitment of 150,000 ROXUS prescription units during the first 12 months of its US telehealth arrangement. The company also said roughly 100,000 device components had been received to support supply.

The initial fulfilment confirms that the operational pathway is active, but it does not establish the pace at which prescriptions may build. LTR Pharma said further updates would be provided when meaningful information on US prescription activity becomes available.

Financial Position and Clinical Data

LTR Pharma reported cash of A$19.6 million, no debt and an average quarterly net operating outflow of A$2.8 million in its October 2026 investor presentation. These figures provide context for the company's commercial and development activities without indicating future revenue or funding requirements.

The same presentation reported a Phase II result showing a median time to peak of 10 minutes for ROXUS compared with 60 minutes for oral vardenafil. It also stated that no serious adverse events, Grade 3 or higher events, or discontinuations were recorded in that study. A separate 147-patient real-world study reported a 68% response rate across the cohort.

Separate US Regulatory Pathway

LTR Pharma distinguishes the compounded ROXUS access route from SPONTAN, its product intended for an FDA regulatory pathway. The company said its pharmacokinetic dataset is complete and that pre-IND alignment with the regulator has been achieved. It targets the start of Phase III activity in the first half of 2027 and an FDA submission in the second half of 2027. These remain company targets rather than regulatory approvals or confirmed outcomes.

Key Insights

The first US ROXUS prescription fulfilment is an operational milestone because it demonstrates that LTR Pharma's 2026 telehealth and pharmacy pathway has moved into patient supply. The scale and financial contribution of this activity remain unquantified, while the company continues to pursue a separate regulatory programme for SPONTAN. Future updates on prescription activity and clinical development will provide additional information on progress across both pathways.